Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 2.

Journal Article

Dreger, P., Boumendil, A., Koster, L., Scheid, C., Passweg, J., Veelken, H., Cahn, Y., Collin, M., Wilson, K., Bazarbachi, A., Mayer, J., Corradini, P., Hunault-Berger, M., Parody Porras, R., Gribben, J., Bittenbring, J., Wolff, D., Charbonnier, A., Cambier, N., Montoto, S., Kroeger, N. and Schetelig, J. (2017). No evidence for an increased GVHD risk associated with post-transplant Idelalisib given for relapse of chronic lymphocytic leukemia or lymphoma: First results of a survey by the EBMT chronic malignancy and lymphoma working parties. Bone Marrow Transplant., 52. S. S424 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Dreger, P., Michallet, M., Bosman, P., Sobh, M., Boumendil, A., Nagler, A., Scheid, C., Cornelissen, J., Mueller, L., Niederwieser, D., Vandenberghe, E., Scortechini, I., Schoemans, H., Andersen, N., Finke, J., Russo, D., Ljungman, P., Passweg, J., van Gelder, M., Durakovic, N., Labussiere, H., Berg, T., Wulf, G., Bethge, W., Stilgenbauer, S., Mordini, N., Schaap, M., Fox, C., Kroeger, N., Montoto, S. and Schetelig, J. (2017). Ibrutinib for bridging to allogeneic hematopoietic stem cell transplantation (alloHCT) in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is safe and effective: Updated results of a study by the EBMT Chronic Malignancy and Lymphoma Working Parties, the French Cooperative Group for CLL, and the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant., 52. S. S99 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

This list was generated on Tue Mar 9 01:25:08 2021 CET.